Servier Pharmaceuticals company information, Employees & Contact Information

Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey PR Newswire

JPM25: As Servier cements oncology bona fides, US chief stresses importance of 'staying authentic' Fierce Pharma

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US Fierce Biotech

David Lee: Staying true to our purpose at Servier Pharmaceuticals Oncodaily

Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA BioSpace

Biopharma’s best kept secret opens its doors to new partners statnews.com

Read the editorial of Olivier Laureau Servier

Servier pays big for ex-US darovasertib rights The Pharma Letter

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors PR Newswire

US FDA approves Servier's brain tumor treatment Reuters

2025 Servier R&D Day - MassBio Massachusetts Biotechnology Council

Servier’s US push takes shape as Boston HQ opens BioPharma Dive

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport statnews.com

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 Servier

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says Fierce Pharma

2025 Servier R&D Day: Decisively Science Driven Massachusetts Biotechnology Council

Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey PR Newswire

Integrated annual report 2023/2024 Servier

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide PR Newswire

Servier Wins Reuters' 2022 Patient Champion Award PR Newswire

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) PR Newswire

Desmond Murphy Starts a New Role as U.S. Oncology Assets Liaison at Servier Pharmaceuticals Oncodaily

Servier takes aim at US oncology market, doubling R&D lab space in Boston Fierce Biotech

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma PR Newswire

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma PR Newswire

Servier Showcases Robust Presence at ASH 2019 PR Newswire

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma PR Newswire

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma PR Newswire

Servier to Acquire Agios Pharmaceuticals' Oncology Business PR Newswire

Servier completes its retreat from cell therapy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business PR Newswire

Servier pockets ex-US rights to IDEAYA’s eye cancer drug in $530M deal FirstWord Pharma

Servier picks Shire executive to run U.S. business being built out of deal for Shire’s oncology unit Fierce Pharma

Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor Fierce Pharma

Servier completes acquisition of Agios Pharmaceuticals’ oncology business Servier

Servier acquires Kaerus Bioscience’s FXS candidate for US$450m European Biotechnology Magazine

Servier found guilty of fraud, manslaughter in long-running case over deadly weight-loss pill Fierce Pharma

Servier unveils new cancer-focused Seaport R&D campus The Business Journals

More lab space: French pharma Servier is growing its cancer business in Seaport The Boston Globe

Servier launches U.S. cancer business with plans to double headcount in next 5 years The Business Journals

The 37-year-old CEO of a major pharma company lays out the three-part strategy that drove his career businessinsider.com

Servier opens Kendall Square site, plans Chinese office to access external innovation Fierce Biotech

Servier severs CAR-T collab with Allogene, handing back rights outside the US to 3 candidates Fierce Biotech

Et voilà! New name takes top spot in reputation ranking by US patient groups Fierce Pharma

Olivier Laureau, Servier: Free to Grow, Innovate Pharmaceutical Executive

Servier, armed with Shire cancer drugs, builds out vision for U.S. future Fierce Pharma

NANOBIOTIX Appoints Bart Van Rhijn as Chief Financial Officer citybiz

Servier expands global footprint post Shire deal pharmaphorum

Intarcia And Servier Sign Ex-U.S. Partnership For ITCA 650 In Diabetes; Intarcia Retains Independence & Full Control Of The U.S. & Japan PR Newswire

Amgen buys US rights to Servier’s Procoralan PMLiVE